BioCentury
ARTICLE | Clinical News

Hua starts U.S. Phase I trial of diabetes candidate

February 8, 2019 8:46 PM UTC

Hua Medicine Ltd. (HKEX:2552) began a Phase I trial of its dorzagliatin (sinogliatin, HMS5552, RO5305552) in combination with Januvia sitagliptin in patients with Type II diabetes...

BCIQ Target Profiles

Glucokinase (GCK) (GK)